

PCTWORLD INTELLEC
Int

INTERNATIONAL APPLICATION PUBLISHED

**(51) International Patent Classification ⁶ :****A61K 31/725, 31/73****A****WO 9602258A1****(43) International Publication Date:** 1 February 1996 (01.02.96)**(21) International Application Number:** PCT/SE95/00856**(22) International Filing Date:** 13 July 1995 (13.07.95)**(30) Priority Data:**

9402529-3

19 July 1994 (19.07.94)

SE

(71) Applicant (for all designated States except US): ASTRA
AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).**(72) Inventors; and****(75) Inventors/Applicants (for US only):** HANSSON, Hans-
Arne [SE/SE]; Doteviksvägen 8, S-436 58 Hovås (SE).
JOHANSSON-RUDEN, Gunilla [SE/SE]; Bergstigen 20,
S-436 42 Askim (SE). LARM, Olle [SE/SE]; Nyängsvägen
86, S-169 39 Bromma (SE).**(74) Agent:** ASTRA AKTIEBOLAG; Patent Dept., S-151 85
Södertälje (SE).**(81) Designated States:** AM, AT, AU, BB, BG, BR, BY, CA, CH,
CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE,
KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT,
BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD,
SZ, UG).**Published***With international search report.***(54) Title:** ANTI-ADHESION AGENT**(57) Abstract**

The use of chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate and dextran sulphate for the manufacture of an agent capable of preventing or substantially reducing undesirable adhesion of damaged tissue with adjacent or surrounding tissues in connection with wound healing; and a process for the use of such agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ANTI-ADHESION AGENT

5 Technical area

The present invention relates to new anti-adhesion agents, i.e. products having the ability to prevent non-desired adhesion of tissues in connection with wound healing. The product has also the ability to improve healing quality by stimulating
10 regeneration of tissue.

The invention also includes a process to prevent such undesired adhesion of tissues.

15

Background of the invention

Our ability to move freely as desired and according to the current need is of utmost importance for our life quality. Suitable function of the musculoskeletal
20 system in close cooperation with mainly the skin, mucosal membranes and nervous tissue is a prerequisite for our ability to move and requires per se that different structures such as bone, muscles and tendons are freely moveable relative to each other. Such activities require sliding zones, minimal friction and maximized freedom to move. Sliding systems between for example adjacent
25 muscles and tendons as well as between skin and adjacent tissues are thus required for optimal function. The same is true for visceral structures, such as the gastrointestinal tract, heart, lung, brain and spinal cord. The sliding systems are formed by thin sheets of loose connective tissue, which in the abdomen, thoracic cavity, pericardial space and for the brain and spinal cord are delimited by
30 mesothelial cells. The paratenons show a similar design.

These sliding systems are very sensitive to inflammation and injury. Scar tissues are easily formed resulting in impaired function and even loss of function.

Adhesions may be formed in the abdominal cavity, i.e. formation of strings, and membrane-like fusions of adjacent or surrounding structures may eventually

- 5 result in ileus, a life threatening condition. Surgical procedures carried out to treat injuries, remove tumors or treat other disorders or for performing reconstructions always result in scar formation and thereby more or less comprehensive loss of "natural and original" sliding systems.

- 10 The healing of injuries to the skin and mucosal linings are complicated, on the one hand by the restricted ability of connective tissue to regenerate and on the other hand by the formation of immature granulation tissue, which latter has a limited capacity to gain a maturity similar to that of normal tissue. Thus, the dermis is neither reformed in youths nor in adults after injury with few exceptions. Small
- 15 and/or superficial injuries to the dermis are healed by replacement of the lost tissue by generation of adjacent type like structures and by the generation of reactive granulation tissue. More extensive tissue losses, such as after deep burns, third degree thermal injuries, and after loss of part of the dermis inevitably heal with scar formation, variable but persistent loss of tissue and with permanent
- 20 deformations. The mechanically resistant component in the scar tissue is largely constituted by the type III collagen of short fibres and inferior organisation and has therefore inferior mechanical properties as compared to collagen of the normal optimal type I. The fraction of amorphous plastic ground substance has been reduced as well as the tissue cellularity. The number of blood vessels is with time
- 25 reduced in relation to that in normal tissue and the distribution and type of vessels have changed. Wide, thin-walled vessels of inferior function as compared to the corresponding normal blood vessels are frequent, as are abnormal lymph vessel systems. The sliding systems are thus eventually replaced by rigid, fibrous collagen connective tissue.

An additionally complicating, very important factor is created by the appearance of *myofibroblasts*, i.e. "common" connective tissue cells (fibroblasts) which, as well as a part of the macrophages, have an increased number of cytoplasmic bundles of muscle proteins which enable the cells to slowly and powerfully contract and maintain the contraction for a long period of time. This may result in contractures which further deform and limit the function of the affected tissue. An increased presence of myofibroblasts is seen for example around breast implants (silicon prosthesis implanted for breast enlargement or breast reconstruction; a more detailed description by C. Lossing & H-A Hansson is found in an article in Plastic Reconstr.Surgery 1993, Vol. 91, page 1277-1286) and around sutures and other implants of foreign materials. Myofibroblasts are prevailing at an increased frequency around joints in certain rheumatoid diseases and may result in deviation of fingers and sometimes also in luxations. This cell is the pathogenic factor causing the deformities of the hand striking patients with Dupuytren's contracture. The myofibroblasts as well as common fibroblasts are attached to collagen threads by means of specific heterodimeric receptors, one unit of which always is constituted by $\beta 1$ -*integrin*. Blocking of integrins results in elimination of contractures. Inflammation reducing drugs may influence the expression of integrins.

Sliding systems in loose connective tissue with or without a well defined sliding surface thus only restores in cases with minimal inflammation. The formation of granulation tissue occur, however, only in conjunction with an inflammatory process which per se does result in formation of immature cells and tissue components. This inability of the new tissue formed during the repair process to approach the normal differentiation levels is the reason for that scar tissue is of inferior quality quantitatively and qualitatively as compared to the original, mature but lost tissue. Maturation of regenerated tissue requires access to growth factors which control and promote differentiation of cells, fibres and ground substance.

Background art

Extensive research has been directed to solve the problem of avoiding undesired adhesion of tissues in connection with the healing of wounds, for example wounds
5 caused by surgical incisions, by accident, inflammations and tumors. PCT application No. US90/02406 describes technology associated with this specific problem and also includes a relatively extensive elucidation of the background art. The techniques described in said patent application is based on the use of sandwich constructions comprising a biodegradable bioactive membrane, the
10 opposed surfaces of which have different composition and thereby different biological functions. However, the corresponding products do not seem to be available on the market.

15 Summary of the invention

Accordingly, the present invention has for an object to provide an anti-adherence agent with the use of which there is induced only a minimal inflammation of short duration, said agent being, moreover, bioacceptable and biodegradable without
20 resulting in interfering degradation products.

Another object of the invention is to provide an anti-adherence agent having the ability to induce interface surfaces and resulting in simplified mechanical and technical handling in connection with for example surgical incisions.
25

Yet another object of the invention is to provide a process to prevent or substantially reduce undesirable adhesion of adjacent or surrounding tissues and organs in connection with wound healing.

30 A further object of the invention is to stimulate regeneration of tissue in connection with wound healing.

For these and other objects which will be elucidated by the following disclosure there is provided through the present invention a new use of chitosan and a polysaccharide immobilized thereto, said polysaccharide being selected from heparin, heparan sulphate and dextran sulphate. While using this composition of matter there can be produced an agent having the ability to eliminate or substantially reduce undesirable nt having the ability to eliminate or substantially reduce undesirable adhesion of damaged tissue with adjacent or surrounding tissues in connection with wound healing.

The polysaccharide used can be immobilized to the chitosan in mainly three different ways. Thus, immobilization can take place by ionic binding, by covalent binding or by mechanical inclusion in the chitosan in connection with precipitation from solution. A process for covalent binding of the relevant polysaccharide to a substrate carrying amino groups is described in US patent No. 4,613,665.

As a polysaccharide it is particularly preferred to use heparin or heparan sulphate said substances being commercially available on the market from several manufacturers. Also partly hydrolyzed forms of the polysaccharide can, of course, be used provided that the biological activity is maintained.

The anti-adherence agent used in accordance with the invention can be present in different physical forms, for example as films or membranes, gels, tubes or hoses, powders, aerosols or solutions. The relevant form is, of course, adapted to the damage involved. In most cases films are useful, whereas tubes or gels can be used in special cases, for example in connection with elongate confined tissues, such as muscles and tendons.

Chitosan is a linear 1,4-bound polysaccharide built up from β -D-glucose amine units. The chitosan is manufactured by N-deacetylation of chitin, a polymer forming the shell of inter alia insects and shellfish. Commercially, chitin is recovered from crab and shrimp shells which constitute waste products from the

fishing industry. By controlling the alkaline treatment of chitins chitosans of varying degree of N-acetylation can be made. When treating chitin with concentrated alkali, usually sodium hydroxide, N-deacetylation thus takes place, i.e. acetamido groups are converted into amino groups to form chitosan.

5

The physical properties of chitosan affecting its usefulness depend on the degree of N-acetylation, the molecular weight and the homogeneity. Chitosan is biodegradable, both by chitinase in the digestive system and by lysozyme and other enzymes in the body liquids.

10

It is preferred in connection with the use of the present invention that the chitosan has a degree of N-acetylation of at most about 90% and preferably at most about 50%. It is particularly preferred that the degree of N-acetylation is less than about 25%.

15

The present invention also provides for a process to prevent or substantially reduce undesirable adhesion of tissues in connection with wound healing. This process involves applying at the site of the wound healing an agent comprising chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate and dextran sulphate.

20

Depending on the character of the wound involved the agent can be applied in the form of a film, in the form of a gel or in the form of a tube or a hose. The product to be selected for the application can easily be decided in connection to for example the relevant surgical procedure.

25

Examples of preferred embodiments

The present invention will in the following be illustrated in connection with non-limiting examples. In the examples all films have been prepared in Petri dishes
5 having a surface area of 54 cm².

EXAMPLE 1Preparation of chitosan film

5 g hydrochloride salt of chitosan (50% degree of acetylation, Pronova) are
10 dissolved in distilled water (0.5 L, 1% v/w). 10 mL of the solution obtained are transferred to a Petri dish, and a film of chitosan is formed by evaporation and drying in a heating cabinet at 70°C for 24 h. The film obtained is then neutralized by the addition of a sodium phosphate buffer, 0.2 M, pH 9.0. The film is allowed to remain in the Petri dish in said buffer at room temperature for 2-4 h, is then
15 washed 3-4 times with water and allowed to dry.

EXAMPLE 2Preparation of chitosan film

5 g hydrochloride salt of chitosan (20% degree of acetylation, Pronova) are
20 dissolved in a 2% acetic acid solution (0.5 L, 1% v/w). The solution is autoclaved for 1 h at 125°C for sterilization purposes. After cooling a film is made in a Petri dish, in this case with the use of 20 mL of the solution. The film is then allowed to dry at room temperature and neutralized by the addition of a sodium phosphate buffer, 0.2 M, pH 9.0, added to the dish. The film is allowed to stay in this buffer
25 for 2-4 h at room temperature, is then washed with distilled water 3-4 times and again allowed to dry.

EXAMPLE 3Nitrous acid degradation of heparin

One gram of heparin is dissolved in 300 mL of water. The solution is cooled to 0°C in ice water and maintained cold. First 10 mg of sodium nitrite (NaNO_2) is added.

- 5 Then 2 mL of acetic acid is added to the solution while stirring. The reaction mixture is maintained at 0°C for two hours, dialyzed, and freeze dried. The yield is 0,7 g degraded heparin.

EXAMPLE 4

10 Periodate oxidation of heparin

A solution of sodiumperiodate-oxidized sodiumheparin is prepared in the following manner. One gram of sodiumperiodate, NaIO_4 , is dissolved in 200 mL of distilled water. Ten grams of sodiumheparin is added to the solution of sodiumperiodate and is stirred over night in the dark. The resulting solution, after
15 adding 10 mL of glycerol and stirring for two hours, is dialyzed against water. The water is exchanged every hour. This results in a solution containing periodate-oxidized heparin in a concentration of about 19 mg/mL.

EXAMPLE 5

20 Preparation of chitosan film with covalently bonded heparin (end-point attachment)

- To a neutralized chitosan film prepared in accordance with Example 1 there are added 20 mL of a solution containing 125 mg nitrite degraded heparin, prepared as in Example 3, dissolved in 0.5 L water and containing 4.4 g NaCl. To the
25 solution is added 15 mg sodium cyanoborohydride. The pH of the solution is adjusted to 3.9 using 0.5 M hydrochloric acid or another acid. The solution containing the chitosan film is allowed to stand at room temperature for 14 h, and the treated film is then washed 3-4 times with water and is allowed to dry.

EXAMPLE 6Preparation of chitosan film with covalently bonded heparin (multi point attachment)

A neutralized chitosan film prepared in accordance with Example 2 is allowed to stay for 24 h in 20 mL of the following solution.

4.4 sodiumchloride and 125 mg periodate oxidized heparin, prepared as described in Example 4, are dissolved in 0.5 L of water, the pH is adjusted to 3.9 using 0.5 M hydrochloric acid. To the solution there is added 15 mg sodium cyanoboro-
hydride, and the solution is kept for 10 hours at room temperature. The treated
film is then washed with water 3-4 times and allowed to dry. With regard to
details concerning this technique of covalent binding of heparin reference is made
to the above-mentioned US patent No. 4,613,665.

EXAMPLE 7Preparation of chitosan film with ionically bonded heparin.

A neutralized chitosan film is prepared as in Example 2. A solution of heparin (125 g in 0,5L water containing 4.4 g NaCl) is added. After 3 hours at room temperature the film is rinsed with 2x 0.5 L water and dried.

EXAMPLE 8Biological test, control

The film prepared in accordance with Example 2 is used as an anti-adherence membrane in the following animal model.

The abdominal wall of a rat is opened and on each side of the sagittal line there is produced in a surgical manner a wound about 12x10 mm. One defect is covered with a film from Example 2, a piece of about 18x15 mm, whereas as the other defect is left open. The membrane is sutured using Dexon ® 7-0 in such a manner that no suture is exposed in the abdominal cavity.

The result is evaluated after 2 and 4 week. In this connection modest adherences in the abdominal cavity against the membrane are observed, whereas massive adherences could be demonstrated if the tissue defect is not covered by a film.

- 5 The abdominal defect beneath the film heals essentially with scar tissue formation, and there are signs of inflammatory reaction and capsule formation around the film.

EXAMPLE 9

10 Biological test, in accordance with the invention

The film made in accordance with Example 3 is used as an anti-adherence membrane in the following animal model.

- 15 The abdominal wall of a rat is opened and on each side of the sagittal line there is created in a surgical manner a wound of about 12x10 mm.

One defect is covered with film, about 18x15 mm, whereas the other defect is left open. The membrane is sutured in the same manner as in Example 8.

- 20 The wound area left open displayed several adherences in contrast to the wound covered by the film, which had very few if any adherences.

EXAMPLE 10

Preparation of chitosan film with ionically bonded heparin

- 25 5 g hydrochloride salt of chitosan (45% degree of acetylation, Pronova) are dissolved in water (0.5 L, 1% v/w). The solution is autoclaved for 1 h at 125°C for sterilization purposes. After cooling a film is made in a Petri dish, in this case with the use of 20 mL of the solution. The film is then allowed to dry at room temperature and a solution of heparin (125 g in 0,5L water) is added. After 3 hours
30 at room temperature the film is rinsed with 2x 0.5 L water and dried.

EXAMPLE 11

Preparation of chitosan film

5 g hydrochloride salt of chitosan (45% degree of acetylation, Pronova) are dissolved in water (0.5 L, 1% v/w). The solution is autoclaved for 1 h at 125°C for sterilization purposes. After cooling a film is made in a Petri dish, in this case with the use of 20 mL of the solution. The film is then allowed to dry at room temperature and neutralized by the addition of a sodium phosphate buffer, 0.2 M, pH 9.0, added to the dish. The film is allowed to stay in this buffer for 2-4 h at room temperature, is then washed with distilled water 3-4 times and again allowed to dry.

EXAMPLE 12

Biological test in accordance with the invention

Films prepared from chitosan-heparin as described above in Example 10 are positioned to cover wounds (10 x 12 mm, depth 1 mm) prepared on the parietal abdominal wall as described above. An identical wound is prepared on the contralateral side of the abdominal wall, and covered by a Chitosan film as described in Example 11. The occurrence of adherence formation is evaluated after 2 weeks. The wound covered by the heparin-chitosan film lacks adherences while that covered by the plain chitosan film shows a few, minor adherences. Light microscopic examination of the heparin-chitosan film reveals improved healing of the wound, including the extent of covering by mesothelial-like cells, and that there is a less extensive infiltration of inflammatory cells at the interface between the heparin-chitosan film and the wounded abdominal wall tissue than in corresponding area covered by the plain chitosan film.

EXAMPLE 13

Preparation of chitosan-heparin films

5 g hydrochloride salt of chitosan (16% degree of acetylation, Pronova) are dissolved in a 2% acetic acid solution (0.5 L, 1% v/w). The solution is autoclaved for 1 h at 125°C for sterilization purposes. After cooling a film is made in a Petri

dish, in this case with the use of 20 mL of the solution. The film is then allowed to evaporate in an oven at 70°C for 16 h. The film is treated with a 0.1 M NaOH solution for 3 h at room temperature and then washed with distilled water 3-4 times and again allowed to dry in 70°C for 2 h. The resulting film is then transferred to a Petri dish and 30 mL of a sterile solution of native heparin (1% w/v, pig mucosa, Kabivitrum) in 0.2 M phosphate buffer (pH 6.4) is added. The film is kept at room temperature over night and then rinsed with sterile water and dried in a LAF bench. Four more films are prepared as above with the modification that they are treated with 0.5%, 0.1%, 0.01% and 0.00% solutions of heparin respectively. The heparinised films are subjected to elemental analysis which shows that the films contain 1.2%, 0.9%, 1.3%, 0.23 and 0.007% sulfur, respectively. These values correspond to a heparin content of 9.2%, 7.7%, 10.8%, divided into six groups with ten biopsies 1.9% and 0% respectively.

15 EXAMPLE 14

Preparation of in vitro wounds

Sterile human skin is obtained from mastectomy specimens. In each experiment only skin from a single donor is used. Under sterile conditions, circles with a diameter of 6mm are cut with a biopsy punch (Stiefel Laboratories, UK). In the centre of each piece, on the epidermal side, a partial wound is made with a 3mm biopsy punch and subsequently pieces are transferred to 12-well plates (Costar) with the epidermal side up. Each well is filled with Dulbeccos Modified Eagles Medium (DMEM) to the epidermal level keeping the wound in the gas/liquid interface. Fetal Calf serum, 2% (FCS) and antibiotics (penicillin 50 µg/mL and streptomycin 50 µg/mL) are added to all samples.

EXAMPLE 15

In vitro healing test

The in vitro wounds, described in Example 14, are divided into five groups with ten biopsies in each group. Every wound is covered with a heparinised film as described in Example 13. The media are changed every day. After seven days the

pieces are fixed in 4% neutral buffered formaldehyde, dehydrated through an ethanol-xylene series and embedded in paraffin. Cross sections, 10-20 mm in thickness are stained with haematoxylin and eosin and the degree of re-epithelialisation is assed by light microscopy. Only wounds totally covered with keratinocytes are regarded as healed.

As is evident from fig 1, films with a heparin content below 2% do not stimulate cellproliferation.

10 EXAMPLE 16

Preparation of gel compositions

Water containing 0.9% NaCl is used to prepare the following four gel compositions:

A=2% Methylcellulose

15 B=2% Methylcellulose + 0.2% Sodiumheparin

C=0.5% Methylcellulose + 1% Chitosan (16% acetylation)

D=0.5% Methylcellulose + 1% Chitosan (16% acetylation) + 0.2 % Sodiumheparin

EXAMPLE 17

20 In vitro healing test

The invitro wounds, described in Example 14, are divided into six groups with ten biopsies in each group. Every wound in five of the groups are covered with a gel composition as decribed in Example 16. The last group is only treated with the media (2% FCS). The media are changed every day. After seven days the pieces are fixed in 4% neutral buffered formaldehyde, dehydrated through an ethanol-xylene series and embedded in paraffin. Cross sections, 10-20 mm in thickness are stained with haematoxylin and eosin and the degree of re-epithelialisation is assed by light microscopy. Only wounds totally covered with keratinocytes are regarded as healed.

As is evident from fig 2, a gel consisting of a combination of Chitosan and Heparin heals the wounds better than gels with only Chitosan or only Heparin does.

EXAMPLE 18

5 Biological test, in accordance with the invention

Example 9 is repeated using the film made in accordance with Example 7.

As is clear from the biological experiments described above the use of the techniques according to the present invention allows substantially improved
10 healing properties in view of prevented adhesion and stimulated growth. The invention is not restricted to the examples given above and the scope of the invention is limited only by the scope of the appended claims.

With regard to the application of the invention there can be mentioned that films
15 or membranes, gels or powder prepared as above or solutions can be used in connection with wounds and defects in or on the following organs and structures: abdominal wall; thorax wall; lung; heart-pericardium; central vessels; intestinal tract; urogenital tract; skull; cerebral meninges; spinal cord; tendons; nerves; muscles; bone ; mucosa; cornea, skin etc.

20

Products in the form of tubes or hoses or gels can be used as guides in stimulated growth and concurrently gliding surfaces can be maintained by the fact that adhesion to the environment is avoided. Such products can be used in connection with nerves, tendons and ligaments, intestinal tract, urogenital tracts, blood
25 vessels etc.

Even better stimulation of healing quality can probably be achieved by a combination of this invention with growth factors.

CLAIMS

1. The use of chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate and dextran sulphate for the manufacture of an agent
5 capable of preventing or substantially reducing undesirable adhesion of damaged tissue with adjacent or surrounding tissues in connection with wound healing.
2. The use according to claim 1, characterized in that the polysaccharide is immobilized to the chitosan by means of ionic bonds.
- 10 3. The use according to claim 1, characterized in that the polysaccharide is immobilized to the chitosan by means of covalent bonds.
4. The use according to any one of the preceding claims, characterized in that
15 the polysaccharide is heparin or heparan sulphate.
5. The use according to any one of the preceding claims, characterized in that the agent is in the form of a film or membrane.
- 20 6. The use according to any one of claims 1 to 4, characterized in that the agent is in the form of a tube or a hose.
7. The use according to claim 6, characterized in that the agent is in the form of a gel.
25
8. The use according to claim 6, characterized in that the agent is in the form of a powder, an aerosol or a solution.
9. The use according to any one of the preceding claims, characterized in that
30 the chitosan has a degree of N-acetylation of at most about 90% and preferably at most about 50%.

10. A process to prevent or substantially reduce undesirable adhesion of tissues in connection with wound healing, characterized by applying at the site of the wound healing an agent comprising chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate and dextran sulphate.

5

11. A process according to claim 10, characterized in that the agent is applied in the form of a film or membrane.



12. A process according to claim 10, characterized in that the agent is applied in the form of a gel.

10

13. A process according to claim 10, characterized in that the agent is applied in the form of a tube or a hose.

14. A process according to claim 10, characterized in that the agent is applied in the form of a powder, an aerosol or a solution.

15

1/1Fig 1Fig 2

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00856

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 31/725, A61K 31/73

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS, WPIDS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Journal of Periodontology, Volume 62, No 10, 1991, S. Pitaru et al, "Heparan Sulfate and Fibronectin Improve the Capacity of Collagen Barriers to Prevent Apical Migration of the Junctional Epithelium" page 598 --	1-9
X	US 4326532 A (WALTON J. HAMMAR), 27 April 1982 (27.04.82) --	1-9
X	US 5116824 A (TERUO MIYATA ET AL), 26 May 1992 (26.05.92), column 3, line 1 - line 11 -- -----	1-9

☐ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

19 October 1995

10 -11- 1995

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Anna Sjölund

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00856

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10-14
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/10/95

International application No.

PCT/SE 95/00856

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4326532	27/04/82	AU-B, B- 543926	09/05/85
		AU-A- 7600981	22/04/82
		CA-A- 1148468	21/06/83
		EP-A, A, A 0051354	12/05/82
		SE-T3- 0051354	
		JP-B- 1045373	03/10/89
		JP-C- 1559151	16/05/90
		JP-A- 57089868	04/06/82
US-A- 5116824	26/05/92	DE-A, T- 3688805	09/09/93
		EP-A, A, A 0200574	05/11/86
		SE-T3- 0200574	
		JP-C- 1507636	26/07/89
		JP-A- 61253065	10/11/86
		JP-B- 63059706	21/11/88